SI-BONE (SIBN)

Its core franchise is built around the iFuse platform, a family of triangular titanium implants and procedure-specific tools intended for minimally invasive sacroiliac joint fusion. SI-BONE has expanded the platform over time with products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, broadening its use across joint fusion, spinopelvic fixation, and complex reconstructive procedures. These products are designed to provide mechanical stability while supporting bone integration, which is central to long-term fusion outcomes.

The company sells primarily to hospitals, ambulatory surgery centers, and physicians in the United States, with additional activity in international markets. Its commercial model depends on surgeon education, clinical evidence, reimbursement coverage, and relationships with spine, orthopedic, and neurosurgical specialists.

SI-BONE operates in the broader medical device and spine surgery markets, where adoption is shaped by clinical data, payer policies, and competition from larger orthopedic and spinal implant manufacturers. Its distinctive position comes from its focused specialization in the sacroiliac joint and pelvic fixation, rather than a broad general spine portfolio.